The two papers by Maas et al. (1993a, b) In contrast, studies examining HV A during the steady state have produced less consistent results.
Nevertheless, some highly consistent fmdings have been produced when DA metabolites were measured in CSF and plasma prior to and during neuroleptic treat ment. For instance, seven of eight CSF studies have found neuroleptic treatment to increase homovanillic acid (HV A) and all three studies that examined this issue have found this increase to be unrelated to treatment response (see Kahn et al. 1992) . Similarly, in measuring HV A in plasma all seven studies found neuroleptic treatment to lower plasma-HV A concentrations and all found this decrement to relate to treatment outcome (Davis et al. 1991) .
In contrast, studies examining HV A during the steady state have produced less consistent results.
Cerebrospinal fluid HV A has generally not been found to differentiate schizophrenic patients from healthy con trol subjects, nor has it been found to relate to specifIc schizophrenic symptoms or subgroups (Widerlov 1988) .
Similarly, plasma-HV A concentrations differentiate pa tients from control subjects only in some studies, and the results of studies that tried to link plasma-HV A con centrations to specifIc schizophrenic symptoms, or even to severity of illness, have also been contradictory (see Davis et al. 1991) .
Thus, although the results are conflicting when HV A is used as an indication of baseline DA function, when HVA is used as an index of change in DA func tion, results are remarkably uniform. The latter con sistency may hinge on the relatively large changes in HV A production when DA activity is manipulated. For instance, administration of 1 mg/kg of apomorphine in rats reduces striatal HV A by about one-third, and by about 25% in plasma (Kendler et al. 1982) . Haloperidol
(1 mg/kg) almost quadruples HV A in the striatum and nearly doubles it in the plasma of rats (Kendler et al. 1981) . A single administration of haloperidol roughly doubles plasma-HV A concentrations in human subjects (Davila et al. 1987 (Stanley et a1. 1985; Wester et al. 1990) , correlations between cisternal and lumbar MA metabolite concentrations have only been found in some (Degrell and Nagy 1990), but not other studies (Maraia et a1. 1975) . (Interpretation of these studies is hampered, however, because they examined
[neurologically] ill , not healthy subjects). It has been
proposed that due to the large area, CSF HV A is of cortical rather than subcortical origin. This assumption appears to be supported by the finding that in schizo phrenic patients, blood flow in the dorsolateral prefron tal cortex was correlated with CSF HVA (Weinberger et al. 1988) . In monkeys, CSF HV A reflects HV A in fron tal cortical but not other cortical areas (Elsworth et a1. 1987) . What, if any, brain area is reflected in plasma HV A concentrations in man is unstudied, although it has been proposed that plasma HV A reflects subcorti-
cal DA activity rather than cortical DA activity (Pickar et a1. 1992) . Measurement of HVA in CSF and plasma may provide distinct windows to separate brain areas.
That this may be so, is suggested by a recent study that found a correlation between CSF HV A and negative symptoms (hypothesized to be related to frontal corti· cal dopaminergic deficits) whereas positive symptoms (hypothesized to be associated with increased subcor· tical DA activity) were correlated with plasma-HV A con· centrations (Pickar et a1. 1992) .
Simultaneous tions, in practice it proves to be, at the very least, a promising tool to help elucidate the mechanism of ac· tion of (atypical) neuroleptics.
